Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

BACKGROUND: A growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC), and with these newer options, many questions about optimising treatment remain unanswered. One recommendation that may potentially be overlooked by practitioners is that androgen d...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:World J Urol
Autori principali: Merseburger, Axel S., Hammerer, Peter, Rozet, Francois, Roumeguère, Thierry, Caffo, Orazio, da Silva, Fernando Calais, Alcaraz, Antonio
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2014
Soggetti:
Invited Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512260/
https://ncbi.nlm.nih.gov/pubmed/25261259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-014-1406-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi